Drug-labels.com

Quadracel (Sanofi Vaccines Canada, 20 mcg / 20 mcg / 5 mcg / 3 mcg / 15...): Uses, Side Effects and Dosage

Status:
Current status: Cancelled Post Market Facts
Strength:
20 MCG / 20 MCG / 5 MCG / 3 MCG / 15 LF / 5 LF / 40 UNIT / 8 UNIT / 32 UNIT

Patient Medication Information: uses, side effects, how to take - Quadracel (Sanofi Vaccines Canada, 20 mcg / 20 mcg / 5 mcg / 3 mcg / 15...)

What the vaccine is used for:

QUADRACEL® is a vaccine that is used to help prevent against diphtheria, tetanus (lock jaw), pertussis (whooping cough) and polio. This vaccine may be given to children aged 2 months or older. It may also be given as a booster to children up to age 7.

The majority of children who are vaccinated with QUADRACEL® will produce enough antibodies to help protect them against these 4 diseases. However, as with all vaccines, 100% protection cannot be guaranteed.

What the vaccine does:

QUADRACEL® causes the body to produce its own natural protection against diphtheria, tetanus, pertussis (whooping cough) and poliomyelitis. After your child receives the vaccine, the body begins to make substances called antibodies. Antibodies help the body to fight disease. If a vaccinated person comes into contact with one of the germs that cause these diseases, the body is usually ready to destroy it.

When the vaccine should not be used:

  • Do not give QUADRACEL® to a child who has an

    allergy to any ingredient in the vaccine or has had an allergic reaction after receiving a vaccine that contained similar ingredients.

  • Do not give QUADRACEL® to a person who has

    had a serious nervous system disorder within 7 days after a previous pertussis vaccine. In case of progressive nervous system disorder or uncontrolled epilepsy, vaccination may be considered only after a treatment has been established and the condition is stabilized.

What the medicinal ingredient is:

Each 0.5 mL dose of QUADRACEL® contains: diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine (pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae types 2 and 3) and inactivated polio vaccine.

What the important nonmedicinal ingredients are:

Aluminum phosphate (adjuvant), 2-phenoxyethanol, polysorbate 80. Residual formaldehyde, glutaraldehyde, bovine serum albumin, neomycin, and polymyxin B may be present in trace amounts.

For a full listing of nonmedicinal ingredients see Part 1 of the product monograph.

What dosage forms the vaccine comes in:

QUADRACEL® is a liquid vaccine that is injected into a muscle. A single dose is 0.5 mL.

WARNINGS AND PRECAUTIONS

If your child has any of the following conditions, talk to your doctor, nurse or pharmacist BEFORE the child receives QUADRACEL®:

  • A high fever or serious illness. Wait until the child is better to give the vaccination.
  • An allergy to any component of the vaccine or the container.
  • A serious nervous system adverse event following a previous pertussis vaccination.
  • Diseases of the immune system or taking a medical treatment that affects the immune system. The vaccine may provide your child with a lower level of protection than it does for people with healthy immune systems. If possible, try to postpone the vaccination until after your child has completed the treatment.
  • A bleeding disorder or taking blood-thinning medications. Tell the person giving the injection about your child’s condition. The injection must be done carefully to prevent excessive bleeding.
  • A higher risk of seizure than the general population. A fever-reducing medication (AW) may be given to your child.

IMPORTANT: PLEASE READ

INTERACTIONS WITH THIS VACCINE

DO NOT mix QUADRACEL® with other vaccines or medicinal products in the same syringe.

QUADRACEL® may be given at the same time but at separate sites with Hepatitis B vaccine, 7-valent pneumococcal conjugate vaccine, MMR and Varicella vaccines.

PROPER USE OF THIS VACCINE

Usual Dose:

A single dose of 0.5 mL is recommended for routine immunization of infants at 2, 4, 6 and 18 months of age and in children up to their 7th birthday.

The vaccination should be given in the muscle, preferably in the thigh for children up to 1 year-old. In children >1 year of age, the shoulder is the preferred site since use of the thigh results in limping due to muscle pain.

Overdose:

In case of drug overdose, contact a health-care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:

If immunization is delayed for any reason, the recommended schedule is:

  • 3 single doses of 0.5 mL with 2 months between

    doses

  • a 4th dose given 6 to 12 months after the 3rd dose

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

A vaccine, like any medicine, may cause side effects. Up to one third of children who receive

QUADRACEL® may have mild side effects such as redness, swelling or tenderness around the injection site. Other common reactions include fever, increased crying, fussiness, being less active and have decreased eating. These side effects are usually mild and last no more than 3 to 4 days. Severe reactions, such as high fever, swelling and redness of the entire arm or leg, or a serious allergic reaction are very rare.

Tell your doctor, nurse or pharmacist as soon as possible if your child is not feeling well after receiving QUADRACEL®.

Serious side effects are extremely rare.

This is not a complete list of side effects. For any unexpected effects while taking QUADRACEL®, contact your doctor, nurse or pharmacist. HOW TO STORE THIS VACCINE

Store the vaccine in a refrigerator at 2° to 8°C (35° to 46°F). Do not freeze. Throw the product away if it has been exposed to freezing.

Do not use after the expiration date.

Keep out of reach of children.

REPORTING SUSPECTED SIDE EFFECTS

0K9NOTE: Before contacting HenadINFORMATION

To monitor vaccine safety, the Public Health Agency of Canada collects information on serious and unexpected case reports on adverse events following immunization.

For Health Care Professionals:

If a patient experiences an adverse event following immunization, please complete the appropriate Adverse Events following Immunization (AEFI) Form and send it to your local Health Unit in your province/territory.

For the General Public:

Should your child experience an adverse event following immunization, please ask your doctor, nurse, or pharmacist to complete the Adverse Events following Immunization (AEFI) Form.

If you have any questions or have difficulties contacting your local health unit, please contact Vaccine Safety Section at Public Health Agency of Canada:

By toll-free telephone: (1-866-844-0018) By toll-free fax: (1-866-844-5931) Email: caefi@phac-aspc.gc.ca

Web: http://www.phac-aspc.gc.ca/im/vs-sv/index-eng.php

Mail:

The Public Health Agency of Canada Vaccine Safety Section

130 Colonnade Road

Ottawa, Ontario

K1A 0K9

A/L 6502A

NOTE: Should you require information related to the management of the side effect, please contact your health care provider before notifying the Public Health Agency of Canada. The Public Health Agency of Canada does not provide medical advice.

MORE INFORMATION

This document plus the full product monograph, prepared for health professionals can be found at:

http://www.sanofipasteur.ca

You may also contact the vaccine producer, Sanofi Pasteur Limited, for more information. Telephone: 1-888-621-1146 (no charge) or 416-667-2779 (Toronto area). Business hours: 8 a.m. to 5 p.m. Eastern Time Monday to Friday.

R12-0811 Canada

About this document

Source: Health Canada – Drug Product Database (DPD) and product monographs · DIN (Drug Identification Number): 02230946

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Quadracel (Sanofi Vaccines Canada, 20 mcg / 20 mcg / 5 mcg / 3 mcg / 15...)

DIN 02230946
Schedule(s) SCHEDULE D
Active ingredient(s) Pertussis toxoid 20 MCG, Filamentous haemagglutinin 20 MCG, Fimbriae 5 MCG, Pertactin 3 MCG, Diphtheria toxoid 15 LF, Tetanus toxoid 5 LF, Inactivated poliomyelitis vaccine (dc-o.) type 1 mahoney 40 UNIT, Inactivated poliomyelitis vaccine (dc-o.) type 2 mef1 8 UNIT, Inactivated poliomyelitis vaccine (dc-o.) type 3 saukett 32 UNIT
Dosage form(s) Suspension
Route(s) of administration Intramuscular
Drug class (WHO ATC)
  1. J Antiinfectives for systemic use
    1. J07 Vaccines
      1. J07C Bacterial and viral vaccines, combined
        1. J07CA Bacterial and viral vaccines, combined
          1. J07CA02 Diphtheria-pertussis-poliomyelitis-tetanus
Company SANOFI VACCINES CANADA LTD.
Current status Cancelled Post Market
Current status date November 12, 2024

Source: Health Canada – Drug Product Database (DPD) and product monographs, data as of November 1, 2026. Data from the Health Canada Drug Product Database, as published there. Not a substitute for the advice of a doctor or pharmacist.